NewLimit
- Health & Biotech
- South San Francisco, California, US
- Founded 2021
- Private
- newlimit.com
Develops epigenetic reprogramming therapies that aim to restore youthful function to aging cells, starting with the liver and immune system.
$565MEquity raised in 2025–20262025 $130M · 2026 $435M · 2 equity rounds
$605MEquity raised, all time3 equity rounds on record
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 3 rounds · 4 sources · newest first
- Series CAmount$435MPost-money—✓ Confirmed
- Series BAmount$130MPost-money—◔ Reported
- Series AAmount$40MPost-money—◔ Reported
Investors 17
- Founders Fund3
- Kleiner Perkins3
- Daniel Gross2
- Dimension2
- Elad Gil2
- Garry Tan2
- Nat Friedman2
- Abstract Ventures
- Eli Lilly
- Fred Ehrsam
- Greenoaks
- Human Capital
- Khosla Ventures
- Patrick Collison
- Quiet Capital
- Thrive Capital
- Valor Equity Partners
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
RampFintech · $3.6B in 2025–2026Shared: Founders Fund, Khosla Ventures +2CognitionAI Apps · $3.4B in 2025–2026Shared: Kleiner Perkins, Founders Fund +1NeuralinkHealth · $650M in 2025–2026Shared: Founders Fund, Thrive Capital +2Chai DiscoveryHealth · $600M in 2025–2026Shared: Dimension, Kleiner Perkins +1Anduril IndustriesDefense · $7.5B in 2025–2026Shared: Founders Fund, Thrive CapitalCrusoeAI Infra · $5.3B in 2025–2026Shared: Founders Fund, Valor Equity Partners
Also in the South San Francisco hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. NewLimit and its logo are trademarks of their owners, used here for identification only.
